Chiromics, a drug discovery company, has formed a collaboration with global healthcare company GlaxoSmithKline to discover novel classes of small molecules against certain biological targets.

Chiromics' compound collections are assembled using Chiromics' core chemical technology referred to as "cascade catalysis." The technology was invented in the MacMillan Laboratories at Princeton University. Cascade catalysis allows for the creation of "accessible complexity"—a diverse collection of molecules that is more complex than and differentiated from currently existing small molecule collections, while retaining drug-like properties, the ability to develop structure-activity relationships and ease of re-synthesis.

The combination of Chiromics' chemical compound collection of accessible complexity, and Chalis, Chiromics' exclusive hit recognition algorithm for Affinity Screening, provides an opportunity for identification of new molecules that is complementary to conventional high throughput screening processes.

"We are pleased to enter into this collaboration with GSK. This collaboration further validates that our chemical technology and discovery platform is a potentially valuable gateway to a new set of small molecules for drug discovery,” said David MacMillan, Ph.D., founder of Chiromics.